直 Japanese PDF Font
  • Our Professionals
  • Our Work
  • Our Insights
  • Offices
  • Firm
  • Careers
Finnegan
  • Articles & Books
    • Ad Law Buzz Blog
    • At the PTAB Blog
    • European IP Blog
    • Federal Circuit IP Blog
    • INCONTESTABLE® Blog
    • Prosecution First Blog
  • Events & Webinars
  • IP Updates
  • Podcasts
    • AI + Finnegan
    • AI + Copyright
    • AI + Patent
    • AI + Privacy
    • AI + Trade Secrets
    • AI + Trademark
  • Unified Patent Court (UPC) Hub

At the PTAB Blog

PTAB Statistics for Final Written Decisions Issued in December 2024 and January 2025

February 28, 2025

Authored and Edited by Daniel F. Klodowski; Umber Aggarwal; Deena Kablaoui Lanier; Nicholas A. Eitsert; A. Sasha Hoyt; Elliot C. Cook

In December, the PTAB cancelled 370 (77.57%) instituted claims across 27 IPR and PGR Final Written Decisions, including decisions issued following remand from the Federal Circuit.  After review, 102 (21.38%) instituted claims survived, and patent owners conceded 5 (1.05%) instituted claims through motions to amend or disclaimer.  For comparison, the cumulative average cancellation rate of instituted claims in IPR, CBM, and PGR Final Written Decisions is about 74%.

On a per-case basis, no instituted or substitute claims survived in 15 (55.56%) decisions, all instituted claims survived in 7 (25.93%) decision, and 5 (18.52%) decisions had a mixed outcome in which at least one instituted or substitute claim survived and at least one instituted claim was cancelled.  

In January, a relatively favorable month for patent challengers, the PTAB cancelled 491 (80.49%) instituted claims across 33 IPR and PGR Final Written Decisions. In those decisions, 117 (19.18%) instituted claims survived, and patent owners conceded 2 (0.33%) instituted claims through motions to amend or disclaimer.

On a per-case basis, no instituted or substitute claims survived in 19 (57.58%) decisions, all instituted claims survived in 3 (9.09%) decisions, and a mixed outcome occurred in 11 (33.33%) decisions in January.

Turning to motions to amend that were addressed on the merits in a Final Written Decision, the PTAB has cumulatively granted 662 (15.61%) proposed substitute claims while denying 3,580 (84.39%) proposed substitute claims through January 31, 2025. 

Patentees have had slightly more success with motions to amend in PGRs.  Through January 31, 2025, the PTAB granted 69 (20.60%) proposed substitute claims in PGR motions to amend while denying 266 (79.40%) proposed substitute claims.

The overall cumulative instituted claim survival rate in IPRs, CBMs, and PGRs through January 31, 2025, broken down by technology center, is as follows:

The cumulative number of Final Written Decisions through January 31, 2025, separated by technology center, is as follows:

Additional cumulative statistics on the Board’s IPR, CBM, and PGR decisions, updated through January 31, 2025, are available here on the At the PTAB blog.

Related Practices

Patent Office Invalidation Proceedings

PTAB Invalidation Proceedings: IPR and PGR

Related Offices

Reston, VA

Washington, DC

Contacts

Daniel F. Klodowski
Partner
Washington, DC
+1 202 408 4216
Email
Umber Aggarwal
Associate
Reston, VA
+1 571 203 2423
Email
Deena Kablaoui Lanier
Associate
Washington, DC
+1 202 408 4115
Email
Nicholas A. Eitsert
Associate
Washington, DC
+1 202 408 4157
Email
A. Sasha Hoyt
Associate
Washington, DC
+1 202 408 4230
Email
Elliot C. Cook
Partner
Reston, VA
+1 571 203 2738
Email

Copyright © 2025 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP. 


DISCLAIMER: Although we wish to hear from you, information exchanged in this blog cannot and does not create an attorney-client relationship. Please do not post any information that you consider to be personal or confidential. If you wish for Finnegan, Henderson, Farabow, Garrett & Dunner, LLP to consider representing you, in order to establish an attorney-client relationship you must first enter a written representation agreement with Finnegan. Contact us for additional information. One of our lawyers will be happy to discuss the possibility of representation with you. Additional disclaimer information.

Related Insights

Conference

7th International Conference on Biofuels and Bioenergy

June 25-26, 2026

Edinburgh

Conference

17th Summit on Biosimilars & Innovator Biologics

June 2-3, 2026

New York

Articles

Article_D.-Mass-Patent-Litigation-Update-October-2024

D. Mass. Patent Litigation Update: April 2026

June 1, 2026

At the PTAB Blog

Consistency Is Key – USPTO Issues Three New Informative Decisions

May 29, 2026

At the PTAB Blog

Discretion All the Way Down: USPTO Uses a Discretionary IPR Denial to Justify a    
§ 325(d) EPR Denial

May 28, 2026

Articles

Colorado Replaces Landmark AI Act: An Overview of the New SB 26-189 Framework

May 26, 2026

At the PTAB Blog

IPR and PGR Statistics for Final Written Decisions Issued in March and April 2026

May 26, 2026

At the PTAB Blog

Claim Disclaimer Derails Instituted IPR in Freightcar America

May 26, 2026

At the PTAB Blog

Before the Holding, the Message: Director Squires Uses Magnolia Medical to Outline PTAB Discretionary Denial Policy Changes

May 20, 2026

Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.

  • Privacy
  • Disclaimer
  • Legal Notices
  • Fraud Alert
  • EEO Statement
  • Cookies
  • Contact Us

© 2026 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP